natgillin/translations-raw huggingface dataset:
Tenofovir is primarily excreted by the kidney by both filtration and an active tubular transport system with approximately 70 – 80% of the dose excreted unchanged in urine following intravenous administration.
Tenofovir se prvenstveno izlučuje putem bubrega, filtracijom i aktivnim tubularnim transportnim sustavom, pri čemu se oko 70-80% doze izlučuje u mokraći u nepromijenjenom obliku nakon intravenske primjene.
Tenofovir may decrease the AUC
Tenofovir može sniziti AUC i Cmin
Tenofovir pharmacokinetics were not substantially altered in subjects with hepatic impairment suggesting that no dose adjustment is required in these subjects.
Farmakokinetika tenofovira nije se bitno izmijenila u ispitanika s oštećenjem jetre, što navodi na zaključak da u tih ispitanika nije potrebno prilagođavati dozu.
Tenofovir pharmacokinetics were not substantially altered in subjects with hepatic impairment suggesting that no dose adjustment of tenofovir disoproxil fumarate is required in these subjects.
Farmakokinetika tenofovira nije se bitno izmijenila u ispitanika s oštećenjem funkcije jetre, što navodi na zaključak da u tih ispitanika nije potrebno prilagođavati dozu.
tenofovir plasma concentrations.
koncentracije tenofovira.
tenofovir, it is not recommended to
tenofovir, ne preporučuje se
tenofovir-associated adverse
povezane s primjenom tenofovira,
tenofovir.
tenofovira.
tenofovir/ emtricitabine
tenofovir/ emtricitabin
Tenofovir/emtricitabine
Tenofovir/emtricitabi n
Tenofovir:
Emtricitabin:
Tenofovir:
Etinilestradiol:
Tenofovir:
ustanovljena.
Tenofovir: AUC: ↔
Rilpivirin: AUC: ↔
tenosynovitis (tendonitis, synovitis and tendon pain)
tenosinovitis (tendonitis, sinovitis i bol u tetivama)
tenosynovitiss
tenosinovitiss
Tension
napetost
Tension headache*
tenzijska glavobolja
TEPADINA 15 mg powder for concentrate for solution for infusion thiotepa
TEPADINA 15 mg prašak za koncentrat za otopinu za infuziju tiotepa
Tepadina can be used for transplantation of cells from a donor and for transplantation of cells derived from the patient’s own body.
Tepadina se može koristiti za transplantaciju stanica od donatora i za transplataciju stanica dobivenih iz tijela bolesnika.
TEPADINA does not contain any excipients.
TEPADINA ne sadrži pomoćne tvari.
TEPADINA does not contain any other ingredients.
TEPADINA ne sadrži druge sastojke.
TEPADINA infusion solution should be inspected visually for particulate matter prior to administration.
Otopina lijeka TEPADINA za infuziju se mora prije primjene vizualno pregledati kako bi se isključila prisutnost čestica.
TEPADINA is a white crystalline powder supplied in a glass vial containing 100 mg thiotepa.
TEPADINA je bijeli kristalinični prašak u staklenoj bočici koja sadrži 100 mg tiotepe.
TEPADINA is a white crystalline powder supplied in a glass vial containing 15 mg thiotepa.
TEPADINA je bijeli kristalinični prašak u staklenoj bočici koja sadrži 15 mg tiotepe.
TEPADINA is indicated, in combination with other chemotherapy medicinal products: with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients; when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.
Lijek TEPADINA je indicirana, u kombinaciji s drugim kemoterapeuticima: uz ili bez zračenja cijelog tijela, kao pripremno liječenje prije alogene ili autologne transplantacije krvotvornih matičnih stanica (TKMS) u hematoloških bolesti u odraslih i pedijatrijskih bolesnika; kada je visoko-dozna kemoterapija, uz potporu sa TKMS, prikladna za liječenje solidnih tumora u odraslih i pedijatrijskih bolesnika.
TEPADINA is indicated, in combination with other chemotherapy medicinal products: with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients; when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.
TEPADINA je indicirana, u kombinaciji s drugim kemoterapeuticima: uz ili bez zračenja cijelog tijela, kao pripremno liječenje prije alogene ili autologne transplantacije krvotvornih matičnih stanica (TKMS) u hematoloških bolesti u odraslih i pedijatrijskih bolesnika; kada je visoko-dozna kemoterapija, uz potporu sa TKMS, prikladna za liječenje solidnih tumora u odraslih i pedijatrijskih bolesnika.
Tepadina is used with other medicines before transplantation to destroy the abnormal cells and the patient’s existing blood-making cells.
Tepadina se koristi zajedno s drugim lijekovima prije transplantacije kako bi se uništile abnormalne stanice i postojeće krvotvorne stanice bolesnika.
TEPADINA must be reconstituted with 1.5 ml of sterile water for injections.
TEPADINA se mora rekonstituirati s 1,5 ml sterilne vode za injekcije.
TEPADINA must be reconstituted with 10 ml of sterile water for injections.
TEPADINA se mora rekonstituirati s 10 ml sterilne vode za injekcije.
TEPADINA posology is reported, in adult and paediatric patients, according to the type of HPCT (autologous or allogeneic) and disease.
Potrebno doziranje lijeka TEPADINA kod odraslih i pedijatrijskih bolesnika ovisi o tipu TKMS (autologne ili alogena) i o bolesti.
TEPADINA should be aseptically administered as a 2-4 hours infusion under room temperature (about 25°C) and normal light conditions.
TEPADINA se mora aseptički primijeniti putem infuzije u trajanju od 2-4 sata na sobnoj temperaturi (oko 25 °C) i u uobičajenim uvjetima osvjetljenja.
Teratogenicity warning
upozorenje o teratogenosti
Teratogenicity was noted in rabbits given 1000 mg/kg/day (15 times the exposure from the recommended human dose on an AUC basis).
Teratogenost je primijećena kod kunića koji su primili 1000 mg/kg/dan (15 puta veća izloženost nego kod preporučene doze u ljudi na temelju AUC).
Teratogenicity was noted in rabbits given 1000 mg/kg/day (7.5 times the exposure from the 120 mg/day human dose on an AUC basis).
Zamijećena je teratogenost u zečeva pri davanju 1000 mg/kg/dan (7,5 puta veća izloženost nego izloženost pri dozi primijenjenoj u ljudi od 120 mg/dan na AUC osnovi).
Teratogenicity: Significant teratogenic and/or embryocidal potential have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted, occurring at doses as low as one twentieth of the recommended human dose (see section 5.3).
Teratogenost: ribavirin je pokazao značajan teratogeni i/ili embriocidni potencijal u svih životinjskih vrsta na kojima su provedena odgovarajuća ispitivanja, pri dozama koje su iznosile samo 1/20 doze koja se preporučuje u ljudi (vidjeti dio 5.3).
Teratology studies have been conducted in pregnant rats and rabbits at subcutaneous doses of enoxaparin up to 30 mg/kg/day.
Ispitivanja teratogenosti provedena su na skotnim ženkama štakora i kunića pri supkutanim dozama enoksaparina do 30 mg/kg/dan.
terbinafine, itraconazole, fluconazole, posaconazole, voriconazole – antifungals (used to treat fungal infections)
terbinafin, itrakonazol, flukonazol, posakonazol, vorikonazol - antimikotici (primjenjuju se za liječenje gljivičnih infekcija)
Terbinafine/florfenicol/betamethasone acetate
Terbinafin/florfenikol/betametazon acetat
Terbinafine: 10 mg
Terbinafin (terbinafinum) 10 mg
Terfenadine
Okskarbazepin
Terfenadine
terfenadin
terfenadine (a medicine for allergies),
terfenadin (lijek za alergije),
Terfenadine (used for allergy)
terfenadin (koristi se za liječenje alergija)
terfenadine (used to treat allergies)
terfenadin (primjenjuje se za liječenje alergija),
terfenadine and astemizole - commonly used for allergy symptoms
terfenadin i astemizol – često se koriste za liječenje simptoma alergije
terfenadine and astemizole - for hay fever and other allergies cisapride - for problems with digestion
terfenadin i astemizol – za liječenje peludne groznice i drugih alergija cisaprid – za liječenje probavnih problema
Terfenadine Astemizole (saquinavir/ritonavir)
Terfenadin Astemizol (sakvinavir/ritonavir)
terfenadine is contraindicated due to
kontraindicirana zbog potencijalnih
terfenadine or astemizole (allergic problems)
terfenadin ili astemizol (za alergijske tegobe)
terfenadine, astemizole (commonly used for allergy – these medicines may be available without a prescription);
terfenadin, astemizol (često se koriste protiv alergija – ovi lijekovi mogu biti dostupni i bez recepta);
terfenadine, astemizole (commonly used to treat allergy symptoms - these medicines may be available without a prescription); cisapride (used to relieve certain stomach problems).
terfenadin, astemizol (često se primjenjuju za liječenje alergijskih simptoma – ti se lijekovi mogu izdavati i bez liječničkog recepta); cisaprid (koristi se za ublažavanje određenih želučanih problema).
terfenadine, astemizole (used for allergy),
terfenadin, astemizol (koristi se za alergije),
Terfenadine, astemizole, cisapride, pimozide, halofantrine and quinidine (CYP3A4 substrates)
Terfenadin, astemizol, cisaprid, pimozid, halofantrin i kinidin (supstrati CYP3A4)
terfenadine.
Fenitoin
terfenadine; astemizole (used for hay fever and other allergic conditions),
terfenadin; astemizol (za liječenje peludnih i drugih alergija),
Teriflunomid
(0,73-0,98)
Teriflunomide 14 mg/day was not superior to interferon beta- 1a on the primary endpoint: the estimated percentage of patients with treatment failure at 96 weeks using the Kaplan-Meier method was 41.1% versus 44.4% (teriflunomide 14 mg versus interferon beta-1a group, p=0.595).
Teriflunomid u dozi od 14 mg na dan nije bio statistički superioran interferonu beta-1a u primarnoj mjeri ishoda: procijenjeni postotak bolesnika koji nisu odgovorili na liječenje u 96. tjednu, određen Kaplan-Meierovom metodom, iznosio je 41,1% naspram 44,4% (teriflunomid u dozi od 14 mg naspram interferona beta-1a, p=0,595).
teriflunomide for mult iple sclerosis
teriflunomid za liječenje multiple skleroze
teriflunomide for multiple sclerosis
teriflunomid za liječenje multiple skleroze
Teriflunomide may
(0,91-1,11)
Teriflunomide remains in your blood for a long time after you stop taking it.
Teriflunomid se zadržava u krvi još dugo nakon što ga prestanete uzimati.
terile vial adapter reconstitution device 1 sterile infusion set alcohol swabs
terilni nastavak za bočicu za pripremu otopine 1 sterilni set za infuziju vatice natopljene alkoholom
term, efficacy study conducted according to an agreed protocol.
randomizirano, dugotrajno ispitivanje djelotvornosti sukladno dogovorenom
Terminal half-life (days)
Poluvijek eliminacije (dani)
Terminal half-life following an intravenous single microdose is 2.6 hours.
Poluvrijeme nakon intravenske primjene jedne mikrodoze je 2,6 sati.
Terminal half-life increased from 7.3 to 9.2 hours and total body clearance decreased from 6.1 to 2.4 L/h.
Poluvijek se produljio sa 7,3 na 9,2 sati, a ukupni klirens iz tijela smanjio sa 6,1 na 2,4 l/sat.
Terminal volume of distribution Vz ranged between 0.62 and 0.85 l/kg.
Konačni volumen distribucije Vz bio je u rasponu između 0,62 i 0,85 l/kg.
terminology)
terminologija)
terminology)
terminologija†)
terminology*)
indrom palmarno-plantarne
terminology*)
terminologija*)
Terms actually reported in the study up to the data cutoff date and contributing to the relevant adverse reaction are indicated in parentheses, as listed below.
Pojmovi uistinu prijavljeni u ispitivanju do zaključnog datuma prikupljanja podataka i koji doprinose relevantnoj nuspojavi navedeni su u zagradama kako je naznačeno u nastavku.
teroid creams
teroidne kreme
teroid or corticosteroid medicines (such as fluticasone)
teroidni ili kortikosteroidni lijekovi (poput flutikazona)
teroid tablets or injected steroids
teroidne tablete ili injekcije koje sadržavaju steroide
teroids (e.g. budesonide, dexamethasone, fluticasone propionate, ethinyl oestradiol); medicines that cause a reaction with alcohol (e.g. disulfiram).
teroidi (npr. budezonid, deksametazon, flutikazon propionat, etinilestradiol); lijekove koji uzrokuju reakciju s alkoholom (npr. disulfiram).
teroids (e.g. prednisolone),
teroide (npr. prednizolon),
teroids (except drops, creams, or lotions for eye and skin conditions or inhalers for breathing disorders such as asthma);
teroidi (osim kapi, krema, ili losiona za oči i stanja kože ili inhalatori za poremećaje disanja poput astme);
teroids (such as prednisolone),
teroide (npr. prednizolon),
teroids,
teroide,
TESAVEL can be taken with or without food.
TESAVEL se može uzimati s hranom ili bez nje.
TESLA was an international, multicentre, double-blind, randomised, placebo-controlled 12-week study in 49 homozygous familial hypercholesterolemia patients aged 12 to 65 years.
TESLA je bilo međunarodno, multicentrično, dvostruko-slijepo, randomizirano, placebom kontrolirano ispitivanje u trajanju od 12 tjedana na 49 bolesnika s homozigotnom obiteljskom hiperkolesterolemijom u dobi od 12 do 65 godina.
Test negative animals can be vaccinated, while test-positive cats should be isolated from other cats and retested within 1–2 months.
Životinje s negativnim nalazom mogu se cijepiti, a životinje s pozitivnim nalazom treba izolirati od ostalih mačaka i ponovo testirati u roku od mjesec-dva.
Test result
Rezultat testa
test show prothrombin time is longer tests show low albumin in your blood
nalazi pretraga pokazuju dulje protrombinsko vrijeme nalazi pretraga pokazuju snižen albumin u krvi
Test your blood or urine for ketones.
Provjerite ketone u krvi ili mokraći.
Test your blood sugar level and your urine for ketones as soon as you notice any of the above signs
Provjerite razinu šećera u krvi i prisutnost ketona u mokraći čim primijetite neki od gore navedenih znakova.
Test your blood sugar level.
Provjerite razinu šećera u krvi.
Test your urine for ketones.
Provjerite ketone u mokraći.
Test your urine for ketones.
Provjerite ketone u urinu.
Test your urine or blood, follow your ‘sick rules’, and tell your doctor.
Učinite pretragu urina ili krvi, slijedite upute u slučaju bolesti i obavijestite liječnika.
Test: Date: Result:
Test: Datum: Rezultat:
Test: Test: Date: Date: Results: Results:
Test: Test: Datum: Datum: Rezultat: Rezultat:
Tested against
Ispitan na
Tested against A/Vietnam A/Indonesia A/Vietnam A/Indonesia A/Vietnam A/Indonesia 12 Month Booster 94.1% 93.1% 94.7% 97.2% 100.0% 100.0%
Ispitan na A/Vietnam A/Indonesia A/Vietnam A/Indonesia A/Vietnam A/Indonesia 12-mjesečni booster 94,1% 93,1% 94,7% 97,2% 100,0% 100,0
Testes1
Testisi1
Testicular disorder*, Prostatitis, Breast disorder female, Epididymal tenderness, Epididymitis, Pelvic pain, Vulval ulceration
poremećaj testisa*, prostatitis, poremećaj dojki u žena, osjetljivost epididimisa, epididimitis, bol u zdjelici, ulceracija na vulvi
Testicular pain
bol u testisima
Testicular pain, breast pain, pelvic pain, genital irritation, ejaculation failure
bol u testisima, bol u dojkama, bol u zdjelici, genitalna iritacija, nemogućnost ejakulacije
Testing this pandemic preparedness vaccine helps to predict how people will react to the vaccine at the time of a pandemic, when the virus strain in the vaccine will be replaced by a weakened version of the actual strain causing the pandemic.
Ispitivanje ovog cjepiva za pripravnost na pandemiju pomaže u predviđanju reakcije osoba za vrijeme pandemije, kada će se soj virusa u cjepivu zamijeniti oslabljenom verzijom onoga soja koji je izazvao pandemiju.
Testis
Testisi
Testosterone levels are often below the normal range in patients with end-stage renal disease.
Vrijednost testosterona često je ispod normalna raspona u bolesnika s terminalnom bolesti bubrega.
Tests and check-ups before and during treatment
Pretrage i provjere prije i tijekom liječenja
Tests are available to determine a patient’s CYP2C19 genotype.
Dostupni su testovi za određivanje CYP2C19 genotipa bolesnika.
Tests are available to identify a patient's CYP2C19 genotype (see section 5.2).
Dostupni su testovi za određivanje CYP2C19 genotipa bolesnika (vidjeti dio 5.2).
Tests are available to identify a patient's CYP2C19 genotype.
Dostupni su testovi za određivanje CYP2C19 genotipa bolesnika.
Tests may show abnormal kidney function
pretrage mogu pokazati poremećenu funkciju bubrega
Tests may show: increased cholesterol in the blood
Pretrage mogu pokazati: povišene razine kolesterola u krvi
Tests may show: low blood platelet count, low white blood cells count (neutropaenia), anaemia, fluid around the lungs
Pretrage mogu pokazati: snižen broj krvnih pločica, snižen broj bijelih krvnih stanica (neutropenija), anemija, tekućina oko pluća
Tests or checks
Pretrage ili provjere
tests show higher or lower potassium in your blood
nalazi pretraga pokazuju povišen ili snižen kalij u krvi
tests show higher triglycerides, low density lipo-protein or white cells in your blood tests show abnormal ECG (‘electrocardiogram’)
nalazi pretraga pokazuju povišene trigliceride, lipoprotein niske gustoće ili bijele krvne stanice u krvi nalazi pretraga pokazuju abnormalan EKG ('elektrokardiogram')
tests showing blood in the stools or in the urine bruising and swelling of a wound or injection site
pretrage koje pokazuju krv u stolici ili u mokraći stvaranje modrica i oticanje rane ili mjesta injekcije
Tests will be performed to check the amount of potassium, magnesium, calcium and creatinine in your blood before your first dose of TRISENOX.
Provest će se testovi kako bi se provjerila količina kalija, magnezija, kalcija i kreatinina u Vašoj krvi prije prve doze TRISENOXA.
Tests your doctor will do during treatment
Testovi koje će vaš liječnik raditi tijekom liječenja
tetanus (lockjaw, usually caused by infection of a wound);
tetanusa (obično uzrokovanog infekcijom rane);
tetanus (lockjaw, usually caused by infection of a wound);
tetanusa (čeljusnog grča, obično uzrokovanog infekcijom rane);
Tetanus (often called lock jaw) is usually caused by the tetanus bacteria entering a deep wound.
Tetanus (često zvan zli grč) obično uzrokuje bakterija tetanusa unesena u duboku ranu.
Tetanus (often called lock jaw): caused by the tetanus bacteria entering a deep wound.
Tetanus (često zvan zli grč): uzrokovan bakterijama tetanusa koje ulaze duboko u ranu.
Tetanus component: MERIAL Toulouse 4, chemin du Calquet
Komponenta za tetanus: MERIAL Toulouse
Tetanus toxoid 40 Lf 1
Tetanus toksoid 40 Lf¹
Tetanus toxoid 40 Lf/ml
Tetanus toksoid 40 Lf/ml
Tetanus toxoid 40 Lf2
Tetanus toksoid 40 Lf2
Tetanus Toxoid not less than 40 IU2
Toksoid tetanusa ne manje od 40 IU2
Tetanus Toxoid ≥ 40 IU
Toksoid tetanusa ≥ 40 IU
Tetanus toxoid, adsorbed >/= 40 IU
Infanrix hexa
Tetanus toxoid1 not less than 40 International Units (IU)
Toksoid tetanusa1 ne manje od 40 internacionalnih jedinica (IU)
Tetanus Toxoid1 not less than 40 IU
Toksoid tetanusa 1 ne manje od 40 IU
Tetanus toxoid1  40 IU
toksoid tetanusa1 ≥40 IU
Tetanus: tetanus bacteria enter the body through cuts, scratches or wounds in the skin.
Tetanus: bakterija uzročnik tetanusa ulazi u organizam kroz porezotine, ogrebotine te rane na koži.
tetracycline antibiotics to treat infections such as urinary tract infections
tetraciklinske antibiotike za liječenje infekcija kao što su infekcije mokraćnog sustava
Tetracycline class adverse reactions may include photosensitivity, pseudotumour cerebri, pancreatitis, and anti- anabolic action which has led to increased BUN, azotaemia, acidosis, and hyperphosphataemia (see section 4.4).
Nuspojave tetraciklinskog razreda mogu uključivati fotosenzibilnost, pseudotumor velikog mozga, pankreatitis i antianaboličko djelovanje koje vodi do povišenog BUN-a, azotemije, acidoze i hiperfosfatemije (vidjeti dio 4.4).
Tetracycline class effects
Učinak tetraciklinskog razreda
tetracyclines or sulphonamides (used to treat bacterial infection),
tetraciklini ili sulfonamidi (kojima se liječe bakterijske infekcije),
Tetranor-iloprost is pharmacologically inactive as shown in animal experiments.
Tetranoriloprost farmakološki je neaktivan, što je dokazano u pokusima na životinjama.
TEVA B.V.
TEVAB.V.
TEVA B.V. Swensweg 5 2031 GA Haarlem The Netherlands
TEVA B.V. Swensweg 5, 2031 GA Haarlem, Nizozemska
Teva B.V. Swensweg 5 2031GA Haarlem Netherlands
Swensweg 5 2031GA Haarlem Nizozemska
Teva B.V. Swensweg 5 2031GA Haarlem Netherlands
Teva B.V Swensweg 5 2031GA Haarlem Nizozemska
Teva B.V. Swensweg 5 2031GA Haarlem Netherlands
Teva B.V. Swensweg 5 2031GA Haarlem Nizozemska
Teva B.V. Swensweg 5 2031GA Haarlem The Netherlands
Teva B.V. Swensweg 5 2031GA Haarlem Nizozemska
Teva B.V. Swensweg 5 2031GA Haarlem The Netherlands
Teva B.V., Swensweg 5, 2031GA Haarlem, Nizozemska
Teva B.V., Swensweg 5 2031GA Haarlem The Netherlands
Teva B.V., Swensweg 5, 2031GA Haarlem, Nizozemska
Teva B.V., Swensweg 5,
Teva B.V. Swensweg 5
Teva B.V., Swensweg 5, 2031GA Haarlem, The Netherlands
Teva B.V., Swensweg 5, 2031 GA Haarlem, Nizozemska
Teva B.V., Swensweg 5, 2031GA Haarlem, The Netherlands
Teva B.V., Swensweg 5, 2031GA Haarlem; Nizozemska
Teva Biotech GmbH Dornierstraße 10
Teva Biotech GmbH Dornierstraβe 10
Teva Eesti esindus UAB Sicor Biotech Eesti filiaal
Teva Eesti esindus UAB Sicor Biotec
Teva Eesti esindus UAB Sicor Biotech Eesti filiaal
Teva Eesti esindus UAB Sicor Biotech Eesti Teva Norway AS filiaal
Teva Generics B.V., Computerweg 10, 3542 DR Utrecht, The Netherlands
Teva Generics B.V., Computerweg 10, 3542 DR Utrecht, Nizozemska
Teva Generics GmbH Tel: (49) 351 834 0
Tel: +372 6610801
Teva Gyógyszergyár Zrt Tel.: +36 1 288 64 00
ОД Teva Gyógyszergyár Zrt Tel.: +36 1 288 64 00
Teva Gyógyszergyár Zrt.
Teva Pharmaceuticals Polska Sp. z o.o.
Teva Norway AS
Norway AS
Teva Norway AS Tlf: +47 66 77 55 90
Teva Sweden AB Tlf: (46) 42 12 11 00
Teva Operations Poland Sp. z o.o. ul.
Teva Operations Poland Sp. z.o.o.
Teva Operations Sp.
Teva Operations Sp. z o.o., Ul.
Teva Pharma - Produtos Farmacêuticos Lda Tel: (351) 21 4767550
Teva Pharma - Produtos Farmacêuticos Lda Tel: (351) 214 76 7550
Teva Pharma - Produtos Farmacêuticos Lda Tel: +351 21 476 75 50
Teva Ελλάς Α.Ε. Ελλάδα
Teva Pharma - Produtos Farmacêuticos Lda Tel: +351 214 76 75 50
Teva Pharma - Produtos Farmacêuticos Lda Tel: +351 214 235 910
Teva Pharma - Produtos Farmacêuticos, Lda Tel: +351 21 476 75 50
Teva Pharma - Produtos Farmacêuticos, Lda Tel: ++351 21 476 75 50
Teva Pharma B.V. Swensweg 5, 2031 GA Haarlem The Netherlands
Teva Pharma B.V. Swensweg 5, 2031 GA Haarlem Nizozemska
Teva Pharma B.V. Swensweg 5, 2031GA Haarlem The Netherlands
Teva Pharma B.V. Swensweg 5, 2031GA Haarlem Nizozemska
Teva Pharma B.V., Swensweg 5, 2031GA Haarlem, The Netherlands
Teva Pharma B.V., Swensweg 5, 2031GA Haarlem, Nizozemska.
Teva Pharma Belgium N.V./S.A. Tél/Tél: +32 3 820 73 73
Teva Pharma Belgium N.V./S.A./AG Tél/Tél: +32 3 820 73 73
Teva Pharma Belgium N.V./S.A./A.G. Tel/Tél: +32 3 820 73 73
Teva Pharma Belgium N.V./S.A/A.G Tel/Tél: +32 3 820 73 73
Teva Pharma Belgium N.V./S.A./AG Tel/Tél: +32 3 820 73 73
Teva Pharma Belgium N.V./ Tel/Tél: +32 3 820 73 73
Teva Pharma Belgium N.V./S.A./AG Tel/Tél: +32 3 820 73 73
Teva Pharma Belgium N.V./S.A/AG Tel/ Tél: +32 3 820 73 73
Teva Pharma Belgium N.V./S.A./AG Telephone: (32) 38.20.73.73
Teva Pharma Belgium N.V./S.A./AG
Teva Pharma Belgium N.V./S.A./AG Tél: +32 3 820 73 73
Teva Pharma Belgium N.V/S.A./AG Tél: +32 3 820 73 73
Teva Pharma Belgium S.A./A.G. Tél/Tel: +32 3 820 73 73
Teva Pharma Belgium S.A. ./A.G. Tél/Tel: +32 3 820 73 73
TEVA Pharmaceutical Works Private Limited Company HU-4042 Debrecen
Teva Pharmaceutical Works Private Limited Company Pallagi út 13
Teva Pharmaceutical Works Private Limited Company Pallagi Street 13
Teva Pharmaceutical Works Private Limited Company Pallagi út 13
Teva Pharmaceutical Works, Pallagi út 13, 4042 Debrecen, Hungary
Teva Pharmaceutical Works, Pallagi út 13, 4042 Debrecen, Mađarska
Teva Pharmaceuticals Ireland L-Irlanda
MaltaTeva Pharmaceuticals Ireland L-Irlanda
Teva Pharmaceuticals Ireland L-Irlanda
Teva Pharmaceuticals Irelan L-Irlanda
Teva Pharmaceuticals Ireland Tel: +353 (0)51 321 740
Sími: +358 9 180 452 5900
Teva Pharmaceuticals Ireland Tel: +353 51 321 740
Teva Pharmaceuticals S.R.L Tel: +4021 212 6524
Teva Pharmaceuticals Ireland Tel: +353 51 321740
Teva Pharmaceuticals Ireland Tel: +353 51 3217